Crispr Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $602 | $517 | $504 | $200,000 |
Gross Profit | -10,551 | -56,459 | -51,295 | 180,000 |
EBITDA | -105,391 | -146,415 | -135,754 | 74,483 |
EBIT | -110,191 | -151,260 | -140,587 | 69,583 |
Net Income | -85,942 | -126,408 | -116,591 | 89,347 |
Net Change In Cash | 602 | 517 | 504 | 200,000 |
Free Cash Flow | -107,132 | -96,289 | 109,031 | -96,811 |
Cash | 225,670 | 484,472 | 707,427 | 389,477 |
Basic Shares | 85,234 | 84,920 | 81,794 | 81,324 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $371,206 | $436 | $913,081 | $543 |
Gross Profit | 240,956 | -109,814 | 913,081 | -268,864 |
EBITDA | -202,701 | -648,989 | 391,481 | -345,251 |
EBIT | -222,538 | -673,161 | 373,528 | -354,435 |
Net Income | -153,610 | -650,175 | 377,661 | -348,865 |
Net Change In Cash | 371,206 | 436 | 913,081 | 543 |
Cost of Revenue | -715,804 | -245,513 | 236,616 | |
Free Cash Flow | -272,345 | -532,929 | 457,267 | -256,724 |
Cash | 389,477 | 211,885 | 923,031 | 1,168,620 |
Basic Shares | 79,220 | 77,746 | 80,393 | 65,949 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.01 |
2024-06-30 | -$1.49 |
2024-03-31 | -$1.43 |
2023-12-31 | $1.10 |
